Jeff Schaffnit: Sanofi Highlights Progress in Hemophilia and ITP at ISTH 2026
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared a post on LinkedIn:
“Looking back on the last few days, it’s clear that this year’s ISTH 2026 marked not only an important moment to reflect on the progress being made across rare blood disorders but also a time to reinforce the collective commitment driving innovation forward for patients.
I’m proud of the momentum Sanofi continues to build across our Rare Blood Disorders portfolio, from advances in hemophilia to continued progress in Immune Thrombocytopenia (ITP), where ongoing research is reshaping how we think about disease control.
What stands out most to me is what these milestones represent: years of collaboration among researchers, clinicians, patient communities and teams across Sanofi, all working toward the same goal of improving the day-to-day lives of people living with rare blood disorders.
Thank you to everyone whose dedication to chasing the miracles of science continues to turn scientific progress into meaningful impact for patients and families.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:16Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight